ストックスクリーナーアプリを入手
82.50
3.66%
2.91
アフターアワーズ：
82.79
0.29
+0.35%
前日終値:
$79.59
開ける：
$79
24時間の取引高:
742.90K
Relative Volume:
1.03
時価総額：
$3.68B
収益：
$156.12M
当期純損益:
$-395.33M
株価収益率:
-7.9512
EPS:
-10.3758
ネットキャッシュフロー:
$-292.33M
1週間 パフォーマンス:
+5.81%
1か月 パフォーマンス:
+23.56%
6か月 パフォーマンス:
+54.99%
1年 パフォーマンス:
+145.32%
1日の値動き範囲:
$78.00
$85.49
1週間の範囲:
$75.61
$85.49
52週間の値動き範囲:
$30.82
$118.84
Grail Inc Stock (GRAL) Company Profile
Compare GRAL vs TMO, DHR, NTRA, A, IQV
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
82.50 | 3.48B | 156.12M | -395.33M | -292.33M | -10.38 |
TMO
Thermo Fisher Scientific Inc
|
630.70 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
215.68 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
338.70 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
157.69 | 44.14B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
262.38 | 42.15B | 16.63B | 1.39B | 2.12B | 8.0674 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Mizuho | Neutral |
| 2026-03-18 | アップグレード | TD Cowen | Hold → Buy |
| 2026-02-19 | 開始されました | TD Cowen | Hold |
| 2026-02-17 | 開始されました | Robert W. Baird | Outperform |
| 2025-12-02 | 再開されました | Morgan Stanley | Equal-Weight |
| 2025-11-12 | アップグレード | Guggenheim | Neutral → Buy |
| 2025-04-21 | 開始されました | Canaccord Genuity | Buy |
| 2024-11-27 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-10-17 | 開始されました | Guggenheim | Neutral |
すべてを表示
Grail Inc (GRAL) 最新ニュース
Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone - Stocktwits
Biotech Frenzy Sends GRAIL Soaring Ahead of FDA Showdown - TipRanks
Investigation announced for Long-Term Investors in shares of GRAIL, Inc. (NASDAQ: GRAL) over potential Wrongdoing - openPR.com
GRAIL (GRAL) Earnings Report: Profit Per Share Surpasses Its Benchmark in the Current Update; Post-Report: The Market Price Advances 6.19% in Latest TradingGross Profit Margin - dars.gov.et
Grail Stock Rockets Back As Traders Buy The Dip - TipRanks
GRAIL (GRAL), What Is Behind The Fresh Attention On The Stock? - simplywall.st
Why Silver Grail Resources Ltd stock is skyrocketing today - Wealth Awesome
Russell Investments Group Ltd. Has $1.94 Million Holdings in GRAIL, Inc. $GRAL - MarketBeat
GRAL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
How (GRAL) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
GRAL Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEarnings Season Review - Vinanet
GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting - MarketBeat
GRAL|Grail Inc|Price:68.180|Chg%:-0.760 - TradingKey
Farallon group discloses 9.6% GRAIL, Inc. (GRAL) holding in Schedule 13G/A - Stock Titan
GRAIL Q2 2026 Earnings: EPS Beats Estimates by 5.37% Amid Muted Stock ReactionEarnings Acceleration Picks - Vinanet
GRAIL Inc. (GRAL) Edges Lower 0.84% as Shares Hold Above $64.94 SupportValue Area Low - Vinanet
GRAIL, Inc. (NASDAQ:GRAL) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Bank of America Corp DE Purchases 205,611 Shares of GRAIL, Inc. $GRAL - MarketBeat
GRAIL: Looking Beyond The NHS-Galleri Headline (NASDAQ:GRAL) - Seeking Alpha
GRAIL (NASDAQ:GRAL) Stock Price Down 6.3%What's Next? - MarketBeat
Cancer Detection Firm Nears FDA Breakthrough Blood-Test Review - Streetwise Reports
GRAIL Galleri Test Heads to FDA Panel for Multi-Cancer Screening Review - Streetwise Reports
GRAIL INC : PIPER SANDLER RAISES TARGET PRICE TO $74 FROM $56 - webull.com
FDA panel to review GRAIL’s Galleri multi-cancer blood test in September - Mugglehead Investment Magazine
GRAIL (NASDAQ:GRAL) Trading Up 7.6%Time to Buy? - marketbeat.com
FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Test - Benzinga
FDA panel to weigh Grail’s Galleri test - STAT
GRAIL’s Galleri becomes first multi-cancer detection test headed to US FDA advisory panel - AllSci
Renaissance Technologies LLC Sells 30,100 Shares of GRAIL, Inc. $GRAL - MarketBeat
Illumina Seeks Court Approval of GRAIL Settlement - The Globe and Mail
GRAIL Inc Revenue Breakdown – LSX:A40F8M - TradingView
Is GRAIL (GRAL) Fairly Valued Following Galleri Adoption Growth And The FDA Panel Date? - Yahoo Finance
US FDA to hold advisory meeting to review Grail’s multi-cancer test - WTVB
US FDA to hold advisory meeting to review Grail's multi-cancer test - Reuters
FDA to hold adcomm for Grail cancer test that failed in large, randomized trial - Endpoints News
FDA panel to review GRAIL’s cancer detection test on Sept. 23 - Investing.com
GRAIL Insiders Sold US$29m Of Shares Suggesting Hesitancy - Moomoo
GRAIL to face FDA AdCom for Galleri cancer test (GRAL:NASDAQ) - Seeking Alpha
GRAIL Says FDA Advisory Committee To Review GRAIL Galleri PMA Application On September 23 - TradingView
GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test - PR Newswire
Analysts Offer Insights on NA Companies: GRAIL Inc (GRAL) and SanDisk Corp (SNDK) - The Globe and Mail
State Street Corporation (NASDAQ: GRAL) reports 5.6% beneficial stake in GRAIL - Stock Titan
GRAIL Bets Its Galleri Panel Will Set The FDA Bar For Future MCEDs - insights.citeline.com
Dimensional Fund Advisors LP Purchases 191,857 Shares of GRAIL, Inc. $GRAL - marketbeat.com
PRIMECAP Management (GRAL) discloses 21.8M-share, 5.08% stake in GRAIL - Stock Titan
GRAIL, Inc. 2026: Revenue $44.69M, EPS ($2.56) — 10-Q Summary - TradingView
[10-Q] GRAIL, Inc. Quarterly Earnings Report - Stock Titan
GRAIL (NASDAQ:GRAL) Shares Down 12.2%What's Next? - MarketBeat
GRAL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
GRAIL, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
GRAIL Inc (GRAL) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Grail Inc (GRAL) 財務データ
収益
当期純利益
現金流量
EPS
0.24%
1.51%
大文字化:
|
ボリューム (24 時間):